Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Launched by TANTA UNIVERSITY · Jun 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medicine called cabergoline can help reduce the risk of ovarian hyperstimulation syndrome (OHSS), a serious condition that can happen during fertility treatments when the ovaries respond too strongly to stimulation. OHSS can cause fluid to leak out of blood vessels, leading to swelling and other health problems. The trial aims to see if using cabergoline alongside a technique called "coasting" (pausing stimulation to reduce risk) can lower the chance of developing OHSS.

Women between 18 and 38 years old who are undergoing fertility treatment and are considered at high risk for OHSS might be eligible. This includes those with many developing follicles (small sacs in the ovaries) or high hormone levels during stimulation. Participants should have a healthy body weight and no serious medical conditions like liver or kidney failure, uncontrolled high blood pressure or diabetes, or severe heart problems. If you join the study, you will receive cabergoline as part of your treatment, and doctors will monitor you closely to see if it helps prevent OHSS. It’s important to know that this trial is not yet recruiting, but it is designed to find safer ways to manage fertility treatments for women at risk of OHSS.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age between 18-38 years
• • Body mass index (calculated as weight in kilograms divided by the square of height in meters) \< 30 kg/m2.
• • A long luteal protocol is used for ovarian stimulation.
• • Day 2 FSH \<10 mIU/L and E2\< 50 pg/ml
• • High risk of OHSS, defined as having more than 20 follicles \>12 mm in diameter and/or E2 levels \> 3000 pg/ml when the size of the leading follicle is \> 15 mm
• Exclusion Criteria:
• • The presence of chronic medical diseases, including liver cell failure, renal failure, uncontrolled hypertension, uncontrolled diabetes mellitus, or class 3 or 4 function heart disease in the New York heart association classification.
• • Allergy to Cabergoline.